Journal of Oncology

Bioinformatics in Cancer and Immune Microenvironment 2022


Publishing date
01 Apr 2023
Status
Closed
Submission deadline
25 Nov 2022

Lead Editor
Guest Editors

1Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

2Affiliated Hospital of Zunyi Medical University, Zunyi, China

3University of Münster, Münster, Germany

This issue is now closed for submissions.

Bioinformatics in Cancer and Immune Microenvironment 2022

This issue is now closed for submissions.

Description

Tumor cells do not exist in isolation in the microenvironment of malignancy but rather in a diverse ecosystem that includes not only heterogeneous tumor cell clones, but also normal cell types like fibroblasts, vasculature, and a large pool of immune cells at various stages of activation and differentiation. As a consequence, there is now a complicated interaction of different cellular signaling pathways with the immune cell component influencing cancer development and therapeutic response. To capitalize on potential therapeutic and biomarker findings, it is challenging and time-consuming to thoroughly and systematically characterize these different cell types from diverse tumor samples using immunohistochemistry. We have now entered an era of digital cancer treatment, fueled by the increasing availability of omics technologies, in which varied and global molecular profiling may drive therapeutic discovery and predict immunotherapy responses. Computationally extracting cell-type specific information directly from bulk tumors is one promising answer to this problem. The benefit of using bioinformatics to predict accurate immune signatures from bulk native tumor tissue is that the functional intracellular and intercellular transcriptome profiles are preserved, whereas when purified immune cells are isolated from native tissue, the molecular profiles will have inherently different patterns. Such in silico methods are beneficial because they may capture cell-type specific characteristics as well as cell-cell interactions at the tissue system level.

Predicting tumor patterns accurately and completely is a significant problem to solve, especially considering the effectiveness of immunotherapeutic medication therapy for many human malignancies. This is particularly difficult for subgroups of closely similar immune cell phenotypes with modest gene expression variations but significant functional differences. It will be very beneficial to use bioinformatics strategies to profile the tumor immune landscape because it will allow us to systematically profile one immune cell population's patterns and immune cell networks in tumors with higher resolution, which will aid in the discovery of immune-modulatory drugs.

The goal of this Special Issue is to bring together original research and review articles that will help researchers better understand the complex interactions that exist between tumors, immune cells, and the microenvironment, as well as the discovery of new biomarkers and molecular targets in various cancers.

Potential topics include but are not limited to the following:

  • Bioinformatics research into new cancer diagnosis and treatment methods based on the immune microenvironment
  • Immunological, gene regulatory, and pathophysiological mechanisms involved in carcinogenesis
  • The crosstalk between immune and nonimmune cells in the tumor microenvironment
  • Drug target discovery and targeted drug design
  • Therapeutic strategies that modulate the immune response
  • Meta-analysis to identify the function of tumor microenvironment in cancer

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 2611105
  • - Research Article

Upregulation of APOC1 Promotes Colorectal Cancer Progression and Serves as a Potential Therapeutic Target Based on Bioinformatics Analysis

Weiwei Tang | Hanyuan Liu | ... | Razinah Sharif
  • Special Issue
  • - Volume 2023
  • - Article ID 3677789
  • - Research Article

TREM2 as a Prognostic Biomarker for Osteosarcoma Microenvironment Remodeling

Zhi-Long Shen | Zhao-Yu Chen | ... | Jianru Xiao
  • Special Issue
  • - Volume 2023
  • - Article ID 6922909
  • - Research Article

Association of LAMA1 Single-Nucleotide Polymorphisms with Risk of Esophageal Squamous Cell Carcinoma among the Eastern Chinese Population

Shaoyuan Zhang | Yong Fang | ... | Jun Yin
  • Special Issue
  • - Volume 2023
  • - Article ID 7797710
  • - Research Article

A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs

Su-Zhe Zhou | Ying-Lian Pan | ... | Xiao-Jing Wu
  • Special Issue
  • - Volume 2023
  • - Article ID 2736932
  • - Research Article

Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer

Dongxu Feng | Wenbing Li | ... | Huichao Li
  • Special Issue
  • - Volume 2023
  • - Article ID 1424589
  • - Research Article

Cancer-Associated Fibroblasts Affect Tumor Metabolism and Immune Microenvironment in Gastric Cancer and Identification of Its Characteristic Genes

Chanchan Gao | Fei Liu | ... | Aiping Guo
  • Special Issue
  • - Volume 2022
  • - Article ID 7357566
  • - Research Article

HPV-Related Prognostic Signature Predicts Survival in Head and Neck Squamous Cell Carcinoma

Hongyu Zhao | Fengxu Wang | ... | Jinfeng Ji
  • Special Issue
  • - Volume 2022
  • - Article ID 6906380
  • - Research Article

Identification of Immune and Hypoxia Risk Classifier to Estimate Immune Microenvironment and Prognosis in Cervical Cancer

Yujing Shi | Qing Gao | ... | Xiaoke Di
  • Special Issue
  • - Volume 2022
  • - Article ID 9261339
  • - Research Article

A Connexin-Based Biomarker Model Applicable for Prognosis and Immune Landscape Assessment in Lung Adenocarcinoma

Junqing Qi | Jun Yin | Guowen Ding
  • Special Issue
  • - Volume 2022
  • - Article ID 7248572
  • - Research Article

Identification of a Metabolic Reprogramming-Associated Risk Model Related to Prognosis, Immune Microenvironment, and Immunotherapy of Stomach Adenocarcinoma

Yan Zhao | Dongsheng Zhang | Yueming Sun
Journal of Oncology
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision136 days
Acceptance to publication68 days
CiteScore3.900
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.